Treatment with Myo-Inositol Does Not Improve the Clinical Features in All PCOS Phenotypes
Open Access
- 19 June 2023
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 11 (6) , 1759
Abstract
Background: The aim of the present study is to investigate the effects produced by a treatment with myo-Inositol (myo-Ins) in women presenting polycystic ovary syndrome (PCOS) of different phenotypes. Methods: We performed a retrospective study to evaluate whether patients presenting different PCOS phenotypes, treated for 6 months with myo-Ins, might exhibit a differential response to the treatment. On this premise, we clustered women with PCOS phenotypes A, B, and C in the first study group (hyperandrogenic PCOS or H-PCOS), and women presenting PCOS phenotype D in a separate study group (non-hyperandrogenic PCOS or NH-PCOS) to evaluate if the presence of hyperandrogenism, shared by H-PCOS, might imply a metabolic/endocrine condition rather than a gynecological issue. Results: The administration of myo-Ins induced a significant improvement in metabolic and endocrine parameters in H-PCOS, while the effects on NH-PCOS were negligible. Additionally, myo-Ins treatment improved the endometrial thickness of H-PCOS. Conclusions: Subjects selected for the study exhibited a differential response to myo-Ins therapy according to their PCOS phenotypes. The data suggest that the same treatment might not equally improve the parameters of the PCOS condition in each sub-group of patients. It is crucial to distinguish the various phenotypes to properly select the therapeutical approach.Keywords
This publication has 44 references indexed in Scilit:
- Criteria, prevalence, and phenotypes of polycystic ovary syndromeFertility and Sterility, 2016
- Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOSEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2015
- Hyperinsulinemia Alters Myoinositol to d-chiroinositol Ratio in the Follicular Fluid of Patients With PCOSReproductive Sciences, 2014
- Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controlsEndocrine Journal, 2014
- Potential role and therapeutic interests of myo-inositol in metabolic diseasesBiochimie, 2013
- Divergences in Insulin Resistance Between the Different Phenotypes of the Polycystic Ovary SyndromeThe Journal of Clinical Endocrinology & Metabolism, 2013
- RETRACTED: Contribution of myo-inositol and melatonin to human reproductionEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2011
- Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndromeGynecological Endocrinology, 2009
- Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)Human Reproduction, 2004
- Ultrasound assessment of the polycystic ovary: international consensus definitionsHuman Reproduction Update, 2003